SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.08-2.7%Nov 14 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MARK C. who wrote (6052)10/14/1998 6:27:00 PM
From: Anthony Wong  Read Replies (1) of 9523
 
Heroes and Goats (PFE & MTC)- The Motley Fool Evening News

Oct 14, 1998 (5:56 PM ET)

Drugmaker Pfizer (NYSE:PFE - news) picked up $8 5/8 to $96 1/8 after falling to $87 1/2 in after hours trading yesterday as the market digested the company's fiscal Q3 earnings results. Pfizer's earnings for the quarter came in at $0.51 per share, which was up from $0.45 per share a year ago but $0.06 per share below the Street's mean estimate. Throughout the day, analysts began to dismiss fears that the sky was falling on Pfizer, saying the earnings shortfall could be attributed to the company gearing up to launch new products. Perhaps the most promising new drug on the radar screen is Celebra, which is the first of a new kind of painkilling drug called a Cox-II inhibitor. Pfizer will market the drug under an agreement with Monsanto (NYSE:MTC - news) , which announced today that an FDA advisory panel plans to review its application for Celebra sometime in December.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext